Rengalin

Brand Materia Medica

In stock 1738 Items

Available since: 2019-09-19

All payments are SSL encrypted
Full Refund if you haven't received your order
International shipping to the USA, UK and Europe

Clinical Pharmacology

Other antitussives

R05db

It was experimentally shown that the components of the drug modify the activity of ligand-receptor interaction of endogenous regulators with the corresponding receptors: antibodies to morphine (a component of the drug) modify the activity of ligand-receptor interaction of endogenous regulators with opiate receptors; antibodies to histamine - with histamine H1 receptors; antibodies to bradykinin - with bradykinin receptors; however, the combined use of components leads to increased antitussive effect. In addition to the antitussive action, the complex drug has anti-inflammatory, antiedematous, antiallergic, antispasmodic (antibodies to histamine, antibodies to bradykinin) and analgesic action (antibodies to morphine) due to its constituent components. Due to the modification of histamine-dependent activation of the H1 receptor, bradykinin-dependent activation of the B1 and B2 receptors, the complex preparation Rengalin selectively reduces the excitability of the cough center of the medulla, inhibits the central links of the cough reflex. Inhibiting the centers of pain sensitivity in the thalamus, blocks the transmission of pain impulses to the cerebral cortex. Inhibits the flow of pain impulses from the periphery due to a decrease in the release of tissue and plasma algogens (histamine, bradykinin, prostaglandins, etc.). Unlike narcotic analgesics, it does not cause respiratory depression, drug dependence, does not have a narcotic and hypnotic effect. It relieves the manifestations of acute pharyngitis, laryngitis and bronchitis, reducing bronchospasm. Suppresses systemic and local symptoms of allergic reactions due to the effect on the synthesis and release of histamine and bradykinin from mast cells.

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow to evaluate the content of ultra-low doses of antibodies in biological fluids, organs and tissues, which makes it impossible to study the pharmacokinetics of the drug Rengalin.

Indications

Acute and chronic diseases of the respiratory tract, accompanied by cough and bronchospasm. Productive and unproductive cough for influenza and acute respiratory viral infections, acute pharyngitis, laryngotracheitis, acute obstructive laryngitis, chronic bronchitis and other infectious-inflammatory and allergic diseases of the upper and lower respiratory tract.

Composition

antibodies to bradykinin affinity purified - 0.12 g^*
antibodies to histamine affinity purified - 0.12 g^*
antibodies to morphine affinity purified - 0.12 g^*

Excipients: maltitol 6.0 g, glycerol 3.0 g, potassium sorbate 0.165 g, anhydrous citric acid 0.02 g, purified water to 100 ml.

^* applied to the isomalt as a mixture of three active aqueous-alcoholic dilutions of the substance, diluted in 100, respectively¹², 100³⁰, 100⁵⁰ time

Rengalin is marketed under different brands and generic names, and comes in different dosage forms:

Brand name	Manufacturer	Country	Dosage form
Rengalin	Materia Medica	Russia	solution
Rengalin	Materia Medica	Russia	lozenges

No customer reviews for the moment.

Write your review

Dosage and Administration

For oral use. At one time - 1-2 teaspoons (5-10 ml) - out of meals. It is advisable to keep the solution in the mouth before swallowing for maximum effect of the drug. Apply 1-2 teaspoons 3 times a day. Depending on the severity of the condition in the first three days, the frequency of administration can be increased up to 4-6 times per day. The duration of therapy depends on the severity of the disease and is determined by the attending physician.

Adverse reactions

Possible reactions increased individual sensitivity to the components of the drug. If these side effects are aggravated, or you notice any other side effects that are not listed in the instructions, inform your doctor.

Contraindications

Children's age up to 3 years. Increased individual sensitivity to the components of the drug. Hereditary fructose intolerance (due to the presence of maltitol in the composition). With care: diabetes.

Drug interactions

During the clinical trials, no data were obtained on the interaction of the drug Rengalin with drugs used as concomitant therapy.

Pregnancy and Lactation

The safety of using Rengaline in pregnant women and during breastfeeding has not been studied. During pregnancy and during breastfeeding, the drug is used only if the intended benefit to the mother outweighs the potential risk to the fetus and child. The ratio of benefit / risk is determined by the attending physician.

Special instructions

Patients with diabetes should remember that each teaspoon (5 ml) of the drug contains 0.3 g of maltitol, which corresponds to 0.02 bread units (HE). Insulin is needed for the metabolism of maltitol, although the need for insulin is low due to slow hydrolysis and absorption in the gastrointestinal tract. The energy value of maltitol is 10 kJ or 2.4 kcal / g, which is significantly less than sucrose. The energy value of one teaspoon of the drug is approximately 5.7 kJ (1.37 kcal).

Overdosage

With an accidental overdose, dyspeptic symptoms (nausea, vomiting, diarrhea) are possible, due to the excipients in the preparation (maltitol, glycerol). Treatment is symptomatic.